Webinar: RGX-202 – AFFINITY DUCHENNE Pivotal Program and Functional Data
by: Parent Project Muscular Dystrophy
During this community webinar, REGENXBIO provides an update on its AFFINITY DUCHENNE trial of RGX-202, a next-generation microdystrophin gene therapy. REGENXBIO’s Dr. Naz Dastgir discusses the company’s pivotal trial plans and shares interim clinical data, including the first functional data for RGX-202.
by: Parent Project Muscular Dystrophy
